Coronavirus is declared as a pandemic by the World Health Organization. The death caused by Coronavirus is increasing. In this situation, scientists at the University of Alberta in Canada have good news. They said that Remdesivir can treat coronavirus. The drug is under clinical trials to treat Ebola. It is likely to have the potential for Coronavirus treatment.
Gilead, an American biotechnology company, is researching Remdesivir drugs. Government and non-government organizations are helping Gilead for research. Other local bodies are also helping to test Remdesivir for Coronavirus strain.
In 2014, the outbreak of the West African Ebola virus epidemic commenced the clinical trial of Remdesivir drug. At present, it is reported in phase 2 of clinical development. Lately, the National Institute of Allergy and Infectious Diseases (NIAID) in the US, pioneer the controlled clinical trial for Remdesivir on the hospitalized adult COVID-19 patients. The evaluation for safety and efficacy of the drug of choice to manage Coronavirus and stain was initiated at the University of Nebraska Medical Center in Omaha, US.
At a current press conference held in Beijing; Bruce Alyward, the assistant director of the World Health Organization, said that Remdesivir is the only medical agent that can combat COVID-19. Remdesivir, an analog of 1′-cyano-substituted adenosine nucleotide, is studied to offer broad-spectrum antiviral action against the family of RNA viruses. The mentioned moiety experiences metabolic mechanism that activates nucleoside triphosphate metabolite, thus inhibit viral RNA polymerases. This prevents the replication of the virus.
Bruce Alyward said the result of the ongoing trials with Remdesivir is awaited by April end. However, the final drug engineering can involve another therapeutic moiety to cure the patient of the panic striking COVID-19.
Improvements in the Remdesivir clinical study for COVID-19 treatment are like the breath of fresh air for patients and non-patients! Till then precautions should be taken.